Clinical outcomes of adjuvant radiation therapy and prognostic factors in early stage uterine cervical cancer

Radiation Oncology Journal

Volumn 33, Issue 2, 2015, Pages 126-133

  Kim, Hyun Ju ^a   Rhee, Woo Joong ^a   Choi, Seo Hee ^a   Nam, Eun Ji ^b   Kim, Sang Wun ^b   Kim, Sunghoon ^b   Kim, Young Tae ^b   Kim, Gwi Eon ^a   Kim, Yong Bae ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Adjuvant chemotherapy; Adjuvant radiotherapy; Hysterectomy; Uterine cervical cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUOROURACIL; PACLITAXEL; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; ARTICLE; BRACHYTHERAPY; DISEASE FREE SURVIVAL; DISTANT METASTASIS FREE SURVIVAL; EARLY CANCER; FEMALE; GLYCOLYSIS; HUMAN; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PROGNOSTIC ASSESSMENT; RADIATION DOSE; RADICAL HYSTERECTOMY; RECEIVER OPERATING CHARACTERISTIC; TUMOR VOLUME; UTERINE CERVIX CANCER;

EID: 84936762485     PISSN: 22341900     EISSN: 22343156     Source Type: Journal    
DOI: 10.3857/roj.2015.33.2.126     Document Type: Article

References (21)

1. Landoni F, Maneo A, Colombo A, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 1997;350:535-40.
2. Perez CA, Camel HM, Kao MS, Hederman MA. Randomized study of preoperative radiation and surgery or irradiation alone in the treatment of stage IB and IIA carcinoma of the uterine cervix: final report. Gynecol Oncol 1987;27:129-40.
3. Xue F, Lin LL, Dehdashti F, Miller TR, Siegel BA, Grigsby PW. F-18 fluorodeoxyglucose uptake in primary cervical cancer as an indicator of prognosis after radiation therapy. Gynecol Oncol 2006;101:147-51.
4. Schwarz JK, Siegel BA, Dehdashti F, Grigsby PW. Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA 2007;298: 2289-95.
5. Delgado G, Bundy B, Zaino R, Sevin BU, Creasman WT, Major F. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1990;38:352-7.
6. Rotman M, Sedlis A, Piedmonte MR, et al. A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. Int J Radiat Oncol Biol Phys 2006;65:169-76.
7. Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group Study. Gynecol Oncol 1999;73:177-83.
8. Peters WA 3rd, Liu PY, Barrett RJ 2nd, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000;18:1606-13.
9. Kim S, Oh SW, Kim JS, Kim KH, Kim YK. Prediction of response by FDG PET early during concurrent chemoradiotherapy for locally advanced non-small cell lung cancer. Radiat Oncol J 2014;32:231-7.
10. Seol KH, Lee JE. PET/CT planning during chemoradiotherapy for esophageal cancer. Radiat Oncol J 2014;32:31-42.
11. Siva S, Herschtal A, Thomas JM, et al. Impact of post-therapy positron emission tomography on prognostic stratification and surveillance after chemoradiotherapy for cervical cancer. Cancer 2011;117:3981-8.
12. Boyce J, Fruchter RG, Nicastri AD, Ambiavagar PC, Reinis MS, Nelson JH Jr. Prognostic factors in stage I Carcinoma of the cervix. Gynecol Oncol 1981;12(2 Pt 1):154-65.
13. Chung CK, Nahhas WA, Stryker JA, Curry SL, Abt AB, Mortel R. Analysis of factors contributing to treatment failures in stages IB and IIA carcinoma of the cervix. Am J Obstet Gynecol 1980; 138:550-6.
14. van Nagell JR Jr, Donaldson ES, Wood EG, Parker JC Jr. The significance of vascular invasion and lymphocytic infiltration in invasive cervical cancer. Cancer 1978;41:228-34.
15. Waggoner SE. Cervical cancer. Lancet 2003;361:2217-25.
16. Park JY, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH. Outcomes after radical hysterectomy according to tumor size divided by 2-cm interval in patients with early cervical cancer. Ann Oncol 2011;22:59-67.
17. Huang YT, Wang CC, Tsai CS, et al. Clinical behaviors and outcomes for adenocarcinoma or adenosquamous carcinoma of cervix treated by radical hysterectomy and adjuvant radiotherapy or chemoradiotherapy. Int J Radiat Oncol Biol Phys 2012;84:420-7.
18. Kim YB, Kim GE, Pyo HR, et al. Differential cyclooxygenase-2 expression in squamous cell carcinoma and adenocarcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 2004;60:822-9.
19. Mabuchi S, Okazawa M, Matsuo K, et al. Impact of histological subtype on survival of patients with surgically-treated stage IA2-IIB cervical cancer: adenocarcinoma versus squamous cell carcinoma. Gynecol Oncol 2012;127:114-20.
20. Okazawa M, Mabuchi S, Isohashi F, et al. Impact of the addition of concurrent chemotherapy to pelvic radiotherapy in surgically treated stage IB1-IIB cervical cancer patients with intermediate-risk or high-risk factors: a 13-year experience. Int J Gynecol Cancer 2013;23:567-75.
21. Kidd EA, Siegel BA, Dehdashti F, Grigsby PW. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer 2007;110:1738-44.